[1] |
WANG Haochen, JIA Liqing, YANG Yu, WANG Qian, YU Chengli, TIAN Tian, BI Rui, TU Xiaoyu, BAI Qianming, ZHU Xiaoli, ZHOU Xiaoyan, REN Min.
A study on the correlation between HPV DNA and IHC P16 expression in cervical lesions
[J]. China Oncology, 2025, 35(3): 298-308.
|
[2] |
AN Tianqi, TIAN Jianhui, ZHOU Yiyang, LUO Bin, QUE Zujun, LIU Yao, YU Pan, ZHAO Ruihua, YANG Yun.
Research progress on treatment of pleural effusion related to immune checkpoint inhibitors
[J]. China Oncology, 2025, 35(3): 333-338.
|
[3] |
WU Song, YUAN Yang, JIANG Zefei.
Important clinical studies that changed the clinical practice of advanced breast cancer in 2024
[J]. China Oncology, 2025, 35(2): 186-194.
|
[4] |
ZENG Cheng, WANG Yuanyi, WANG Jiani, MA Fei.
Advances in immune checkpoint inhibitor therapy for breast cancer: research progress and future directions
[J]. China Oncology, 2025, 35(2): 195-204.
|
[5] |
WANG Qing, YU Yushuai, WANG Chenxi, JIANG Zirong, LI Jialu, TANG Shicong, SONG Chuangui.
Current status and prospects of tertiary lymphoid structure heterogeneity in predicting response to neoadjuvant therapy and characterizing immune microenvironment in triple-negative breast cancer
[J]. China Oncology, 2025, 35(2): 213-218.
|
[6] |
LIN Qiuyu, WANG Yuxin, LIN Chenghe.
Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 58-67.
|
[7] |
HUANG Haozhe, CHEN Hong, ZHENG Dezhong, CHEN Chao, WANG Ying, XU Lichao, WANG Yaohui, HE Xinhong, YANG Yuanyuan, LI Wentao.
A CT-based radiomics nomogram for predicting local tumor progression of colorectal cancer lung metastases treated with radiofrequency ablation
[J]. China Oncology, 2024, 34(9): 857-872.
|
[8] |
WU Wen, ZHANG Ruoxin, WENG Junyong, MA Yanlei, CAI Guoxiang, LI Xinxiang, YANG Yongzhi.
Exploring the prognostic value of positive lymph node ratio in stage Ⅲ colorectal cancer patients and establishing a predictive model
[J]. China Oncology, 2024, 34(9): 873-880.
|
[9] |
XIAO Feng, XU Tonglin, ZHU Lin, XIAO Jingwen, WU Tianqi, GU Chunyan.
Significance of infiltration of M1 tumor-associated macrophages in hepatocellular carcinoma
[J]. China Oncology, 2024, 34(8): 726-733.
|
[10] |
GE Zuyin, SONG Kun, LIN Yunxiao, ZHONG Yeling, HAO Jingduo.
The feasibility study of FCGBP and BIGH3 in circulating tumor cells as potential markers for colorectal cancer
[J]. China Oncology, 2024, 34(8): 745-752.
|
[11] |
LIANG Yingyun, CHEN Jianhua.
Application progress of oncolytic virus combined with immunotherapy in the treatment of malignant tumors
[J]. China Oncology, 2024, 34(7): 686-694.
|
[12] |
WENG Junyong, YE Zilan, ZHANG Ruoxin, LIU Qi, LI Xinxiang.
Exploring the guiding role of the number of adverse pathological features in risk stratification for recurrence of stage Ⅰ-Ⅲ colorectal cancer: a retrospective cohort study of 9 875 cases
[J]. China Oncology, 2024, 34(6): 527-536.
|
[13] |
ZHANG Ruoxin, YE Zilan, WENG Junyong, LI Xinxiang.
Correlation study between advanced age and inferior prognosis in stage Ⅱ colorectal cancer patients
[J]. China Oncology, 2024, 34(5): 485-492.
|
[14] |
WANG Xiaocong, LI Ming.
The value of single-cell sequencing in oral squamous cell carcinoma research
[J]. China Oncology, 2024, 34(5): 501-508.
|
[15] |
LIN Yicong, WANG Yue, XUE Qianqian, ZHENG Qiang, JIN Yan, HUANG Ziling, LI Yuan.
Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications
[J]. China Oncology, 2024, 34(4): 368-379.
|